Johns Hopkins Researchers Erase Human Brain Tumor Cells In Mice

Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of — and ultimately left no detectable trace of — brain tumor cells taken from adult human patients.

The scientists targeted a mutation in the IDH1 gene first identified in human brain tumors called gliomas by a team of Johns Hopkins cancer researchers in 2008. This mutation was found in 70 to 80 percent of lower-grade and progressive forms of the brain cancer. The change occurs within a single spot along a string of thousands of genetic coding letters, and is disruptive enough to keep the seemingly innocuous protein from playing its role in converting glucose into energy. Instead, the mutation hijacks the protein to make a new molecule not normally found in the cell, which is apparently a linchpin in the process of forming and maintaining cancer cells.

Encouraged by the new findings, described online Sept. 16 in the open-access journal Oncotarget, the Johns Hopkins researchers say they want to work quickly to design a clinical trial to bring what they learned in mice to humans with gliomas. Despite the growing understanding of IDH1 mutant gliomas, the development of effective therapies has proven challenging, they say.

To read the full article from Johns Hopkins Medicine, please click here.

Share |
August 13, 2015 05:05 PM
Brain Tumor Imaging Protocol will reduce variability in magnetic resonance imaging and increase accuracy in determining progression and response of investigational therapies
July 15, 2015 03:44 PM
Progress continues on the ABC2-funded immunotherapy research by Catherine Flores and her team at UF.
July 14, 2015 03:47 PM
Guest blogger Shawn Peters shares why he's running the 2015 Marine Corps Marathon to support ABC2.

Join us in our fight for a cure!